headache, retrobulbar pain, glaucoma, optic neuropathy caused by the increased intraorbital pressure, 2 and prominent glabellar rhytides. 3 However, not only does Graves ophthalmopathy lead to visual problems, it also has a major impact on daily functioning and well-being. The psychological burden of progressive disfigurement resulting from Graves ophthalmopathy is well recognized. 4 Surgical treatment of Graves ophthalmopathy not only alleviates ocular symptoms, but in so doing, also improves the periocular appearance. Our recommendation for timing of surgical intervention requires that all patients be euthyroid for a minimum of 6 months before any orbital surgery.
As a result of the chronic fibrosis significant of Graves ophthalmopathy, patients typically have upper lid retraction, particularly on downward gaze, involving the levator aponeurosis and upper lid skin. Lower lid retraction and descent are common in these patients as well, because of the similar pathophysiology of chronic fibrosis. In our series, a subset of these patients underwent upper eyelid correction by oculoplastic surgery before being referred to our service. The midface lift and lateral canthoplasty, intrinsic to our surgical approach, is meant to correct the lower lid maladies. Following decompression, patients with persistent upper lid retraction underwent sectioning of the levator aponeurosis with the addition of a müllerectomy where indicated. Augmentation of the infraorbital rim with cheek resuspension further improves globe-rim relations, thereby further refining periorbital aesthetics.
PATIENTS AND METHODS
This study was conducted in accordance with the principles outlined in the Declaration of Helsinki. A lower eyelid transconjunctival incision is performed. A retroseptal dissection is carried through the right lower eyelid. A 7-mm lateral canthal incision is made and the lateral canthus is then released. The arcus marginalis is divided and a subperiosteal orbital dissection is carried for 270 degrees from the medial to lateral wall of the orbit. The midface is also degloved through the transconjunctival incision. The infraorbital nerve is identified and protected. Using a TPS burr (Stryker, Kalamazoo, Mich.), the lateral orbital wall is removed from posterior to the orbital rim back to its junction with the middle cranial fossa. A periosteal elevator is used to infracture the medial wall of the orbital and its ethmoid air cells (Fig. 1) . The medial, central, and lateral orbital fat pads are then partially excised.
An inferior orbital rim implant (Medpor; Porex Surgical, Inc., Newnan, Ga.) (Fig. 2) is then inserted through the lower eyelid incision. Two screws are used to fix the implant in place. The same process is repeated on the contralateral side.
The midface soft tissues are elevated in a subperiosteal plane and sutured to the rim implant at the level of the pupil and lateral canthus. A lateral canthoplasty is performed by suspending the lateral canthus ligament to the Whitnall tubercle or to the zygomaticofrontal suture. A lateral temporary tarsorrhaphy is performed to control postoperative chemosis. Representative cases are shown in Figures 3 and 4 .
Statistical Analysis
Frequency was used to summarize the categorical variables of dry eye versus no dry eye symptoms. A McNemar test was used to test associations between these two categorical variables. A value of p < 0.05 was considered significant. The analysis was performed using SAS 9.2 (SAS Institute, Inc., Cary, N.C.). Assessment of postoperative satisfaction was made by interviewing the patient during follow-up and recording the level of satisfaction reported.
RESULTS
Thirteen patients (26 eyes) with Graves ophthalmopathy were treated with the aforementioned technique at two institutions (Massachusetts General Hospital and Cleveland Clinic) over a 4-year period (2009 to 2012). All patients underwent similar procedures whereby orbital fat was removed, three-wall orbital decompressions were performed, infraorbital rim implants were placed, and a subperiosteal midface lift was conducted. These maneuvers were carried out through transconjunctival incisions of the lower lid with an extension into a lateral canthotomy and occasionally an upper gingivobuccal sulcus incision.
Patients were followed from 6 to 36 months postoperatively, with a median follow-up of 18 months. There was a mean Hertel exophthalmometer improvement of 5.42 mm (range, 4.9 to 6.0 mm). Diplopia resolved in three of 13 cases (23 percent), and no patient had worsening diplopia. Twelve of 13 patients (92 percent) discontinued use of eye lubricants. The McNemar test revealed a value of p < 0.001, which is considered statistically significant and infers significant improvement in the symptom of dry eyes from the preoperative to postoperative state. Patients were asked about their satisfaction with the operation postoperatively. All patients had cosmetic satisfaction and reported high levels of fulfillment. One patient suffered temporary paresthesia to the infraorbital nerve. No infections, hematomas, or ocular complications were reported. Table 1 demonstrates our patients' improvements in exophthalmos, based on their change in Hertel measurements.
DISCUSSION
Graves ophthalmopathy is a chronic autoimmune condition that usually affects both orbits and involves all orbital tissue compartments, including the extraocular muscles, periorbital connective/ fatty tissue, and lacrimal gland. The clinical signs and symptoms of Graves ophthalmopathy reflect the mechanical consequences of increased orbital tissue volume and pressure within the orbit. 5 These consequences lead to an abnormal and symptomatic protrusion of the globes from the orbits of patients. Clinical findings are proptosis, impaired ocular motility, diplopia, lid retraction, and impaired visual acuity up to optic neuropathy, with menacing blindness. The addition of skeletal augmentation to orbit decompression and fat reduction treats symptoms and improves periorbital aesthetics.
Normal globe protrusion varies between sexes and races (Table 2) , as measured by the Hertel exophthalmometer. When a difference of greater than 1.5 mm exists between globes on the same individual, this is considered abnormal. A gross examination of the orbital tissues in patients with active Graves ophthalmopathy reveals edematous, enlarged extraocular muscle bodies in conjunction with an increase in orbital connective and fatty tissue volumes. The orbital inflammatory process is also likely to be driven by T cells that, in response to a yet uncertain antigen, access and infiltrate the orbital space through their interaction with several adhesion molecules. 5 Once the disease has progressed, many various clinical signs, such as proptosis, extraocular muscle dysfunction, periorbital and lid edema, conjunctival congestion, and chemosis, can be explained mechanically by the increase in connective/fatty tissue and extraocular muscle volume within the boundaries of the bony orbits. 6 Many surgical techniques have been described to relieve the orbital symptoms. Tessier 7 advocated moving three walls by impacting the medial orbital wall, lowering the floor, and including a valgus osteotomy of the lateral orbital wall. Wolfe We take a three-tier progressive approach in our experience with patients suffering from Graves ophthalmopathy: intraorbital fat removal, orbital wall removal, and facial skeletal augmentation. Isolated intraorbital fat removal is performed on patients with mild proptosis. It is typically reserved for those cases where primarily fat is involved. The approach is through both lower and upper eyelid incisions. Removing fat volumes between 3 and 6 ml will lead to a correction of exophthalmos between 3 and 6 mm. Orbital wall removal is performed on patients with moderate to severe proptosis. Orbital expansion is the best technique in cases of muscular enlargement and optic neuropathy. Osseous expansion can be performed by means of two-or three-wall removal. Removal of the medial and lateral wall (a balanced orbital decompression) reduces the incidence of postoperative strabismus. Shifting orbital fat tissue medially and laterally into the surgically created periorbital spaces retrudes the globe by diminishing the amount of orbital fat tissue located posterior to the globe. In cases of moderate to severe proptosis, favoring severity (when the relationship of the anteriormost point of the cornea to the malar eminence is of a significant negative vector, as in Fig. 5, left) , augmentation of the craniofacial skeleton with implants is used. This negative vector relationship contributes to the ocular symptoms in Graves ophthalmopathy previously described. Ultimately, the goal is to establish a positive vector (Fig. 5, center) .
With the addition of craniofacial skeletal augmentation and a subperiosteal midface lift at the malar eminence, we have established the socalled reversed negative vector (Fig. 5, right) . The establishment of the reversed negative vector is a combination of both intraorbital and extraorbital surgical techniques that have proven to be of substantial symptomatic relief and improved periocular appearance for patients suffering from severe Graves ophthalmopathy.
CONCLUSIONS
Graves ophthalmopathy is a very complex disorder. Each patient requires a personalized approach, which is why no standardized protocol exists. The choice of treatment depends greatly on the soft-tissue and muscular components of the patient's condition; how advanced the disease is at the time of presentation; the constellation of symptoms the patient presents with; and the surgeon's background, experience, and knowledge of major surgical techniques. Skeletal augmentation is a useful adjunct to orbital decompression and fat excision for treating Graves ophthalmopathy. The combination of balanced orbital decompression and infraorbital rim implants has proven to be reliable, effective, and safe, with good, lasting results. Improvements are made toward the resolution of ocular symptoms and in the patient's personal wellbeing and social life, with a high-benefit-to-lowrisk ratio.
CODING PERSPECTIVE cpt
This information provided by Dr. Raymond Janevicius is intended to provide coding guidance.
67414
Orbitotomy without bone flap (frontal or transconjunctival approach); with removal of bone for decompression 14061-51 Midface soft tissue advancement, 10.1 -30 square centimeters
• The decompression of the orbit is reported with code 67414.
• Code 67414 includes the transconjunctival approach, bone removal, and reconstruction.
• The soft tissue rearrangement of the lower eyelid and midface is reported as an adjacent tissue transfer and is coded by total surface area. If the total surface area exceeds 10 square centimeters, report 14301. • For bilateral procedures report 67414-50 14061-51 14061-59
• Although bilateral midface soft tissue advancements are performed, 14061 is not considered a "bilateral" procedure by CPT rules, so modifier 50 is not appended (as it is for code 67414).
Modifier 59 is used with code 14061. • Some insurance companies will not reimburse for Graves reconstruction unless certain specific criteria are met. Always preauthorize these procedures, in writing, prior to performing the surgery.
